All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00118193" target="_blank" >RIV/00216224:14110/20:00118193 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/20:00073991

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2064" target="_blank" >https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2064</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ejhf.2064" target="_blank" >10.1002/ejhf.2064</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

  • Original language description

    Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) &gt;40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. &gt;300 pg/mL in patients without and &gt;900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Journal of heart Failure

  • ISSN

    1388-9842

  • e-ISSN

    1879-0844

  • Volume of the periodical

    22

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    SI - SLOVENIA

  • Number of pages

    10

  • Pages from-to

    2383-2392

  • UT code for WoS article

    000615960600025

  • EID of the result in the Scopus database

    2-s2.0-85100342570